Due to the current situation related to the coronavirus (COVID-19), study teams may experience delays in responding to signups and scheduling patients on StudyPages.A study team member will respond to you as soon as possible. More coronavirus resources and updates from UC Davis Veterinary Medicine can be found here.

Evaluating biotherapeutic for treatment of UTI in dogs

Enter your info and the study team will contact you soon!
Your data is securely stored and only shared with the research team
Please answer a few questions to see if you may qualify.
Have questions? Please contact the study coordinator Dr. Jodi Westropp at jlwestropp@ucdavis.edu or call (530) 752-1393
By clicking "Next", you're consenting to participate in this questionnaire. There are no right or wrong answers and everything you enter is confidential.
  1. 1. What is your dog's name?
  2. *2. Are you able to bring your dog to visits at UC Davis VMTH?
    Please note there are 3 visits during the two weeks your pet is enrolled in the study.
  3. 3. How did you find out about the study?
  4. 4. What is your preferred method of contact?
Logo Image
"Help us find if the live biotherapeutic, ASB E.coli 212 is effective for treatment of UTI!"
Animal: Dogs
Age: Over 3 months old
Keywords: urinary tract infection, UTI, dog, canine, recurrent, multidrug resistant
Type: Drug/Other
Target:
24 Participants
Investigator:
Background and purpose
Antimicrobial resistance is concerning in both animal and human medicine. Antibiotics are often prescribed for UTI in dogs and finding alternative, effective therapies may help reduce selection of bacterial resistant strains. Dogs with >1 clinical UTI within a 12 month time period as well as dogs with UTI caused by resistant strains of bacteria (multi drug resistant) are eligible for enrollment.
What happens in this study

If you decide to have your dog take part in this study, the following will occur as part of the study:

  • Collect and analyze a blood sample to rule out other diseases
  • Perform an abdominal ultrasound (which may include sedation) to rule out bladder stones, cancer or other abnormalitiesfo
  • Collect and analyze a urine sample for urinalysis and culture if no abnormalities are found
  • Receive EITHER ASB212 (infusion directly into the bladder using a catheter while sedated) OR antibiotic therapy with amoxicillin-clavulanic acid for 7 days. This is a randomized study.
  • Recheck appointments 7 and 14 days later
Pet owner responsibilities

If you wish to have your dog take part in this study, you will be responsible for maintaining a daily diary (requires about 1-2 min per day), and keeping all recheck appointments.

Participation requirements

We are recruiting for dogs that have clinical signs (small amounts of urine frequently, and frequent or painful urination, blood in the urine, straining to urinate or urinary incontinence that has resolved with past antibiotic treatment) and either have had more than 1 UTI in the past 12 months or whose had a multi-drug resistant bacterial strain identified in the urine.

To find out if your dog can take part in the study, your dog will need a complete physical examination, bloodwork done, an SDMA test done to rule out kidney disease, and an abdominal ultrasound. Many of these screening tests are covered by the study.

Benefits and risks of participating
Taking part in this study may lead to successful treatment of your dog's UTI with a non-antimicrobial therapy: a live biotherapeutic, ASB 212. We have reported promising results in a pilot study evaluating this therapy.


If ASB 212 is administered, your dog could experience some initial discomfort from the urinary catheter insertion and/or clinical signs may not improve with treatment. A second infusion could be performed. No major side effects with this therapy were encountered ni our previous pilot study. If Clavamox is administered, your dog could experience mild gastrointestinal signs and/or the clinical signs may not improve with treatment. Sedation (if needed for the ultrasound or urinary catheter insertion) can cause side effects such as a low heart rate, but sedation is often required in clinical patients we will monitor this. In addition to these risks, this study may affect your dog in ways that are unknown. These may be a minor inconvenience or may be very severe.
Compensation
There are no costs for you if you participate in this study. However, we do require the documentation of a urinalysis with bacteria present for enrollment.
Furthermore, if your dog does not respond to therapy (for either group you were randomly assigned to), the study will not cover the recommended treatment or further diagnostics. The study will pay for these tests (not the initial urinalysis), but If any abnormalities are noted, you will be informed of what they are and formal enrollment in the study will not continue.
Resources
Schedule
Study duration and period
This trial will run for 14 days.
Recruitment period
From April 22, 2019
Location
UC Davis Veterinary Medical Teaching Hospital
1 Garrod Drive
Small Animal Clinic - Internal Medicine
Davis, CA 95616
Contact
Dr. Jodi Westropp

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Sending

Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:


E-mail Preview